<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:51:42Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10757508" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10757508</identifier>
        <datestamp>2023-12-31</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah38858" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10757508</article-id>
              <article-id pub-id-type="pmcid">PMC10757508</article-id>
              <article-id pub-id-type="pmc-uid">10757508</article-id>
              <article-id pub-id-type="pmid">37830344</article-id>
              <article-id pub-id-type="pmid">37830344</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.123.030385</article-id>
              <article-id pub-id-type="publisher-id">JAH38858</article-id>
              <article-id pub-id-type="other">JAHA/2023/030385</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Coronary Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With <styled-content style="fixed-case" toggle="no">P2Y12</styled-content> Inhibitors</article-title>
                <alt-title alt-title-type="right-running-head">Aspirin Dosing in Patients Treated With <styled-content style="fixed-case" toggle="no">P2Y12</styled-content> Inhibitors</alt-title>
                <alt-title alt-title-type="left-running-head">Girotra et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah38858-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Girotra</surname>
                    <given-names>Saket</given-names>
                  </name>
                  <degrees>MD, SM</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4784-4513</contrib-id>
                  <xref rid="jah38858-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>saket.girotra@utsouthwestern.edu</email>
                  </address>
                </contrib>
                <contrib id="jah38858-cr-0002" contrib-type="author">
                  <name>
                    <surname>Stebbins</surname>
                    <given-names>Amanda</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0808-9025</contrib-id>
                  <xref rid="jah38858-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0003" contrib-type="author">
                  <name>
                    <surname>Wruck</surname>
                    <given-names>Lisa</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1732-9067</contrib-id>
                  <xref rid="jah38858-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0004" contrib-type="author">
                  <name>
                    <surname>Marquis‐Gravel</surname>
                    <given-names>Guillaume</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2965-1504</contrib-id>
                  <xref rid="jah38858-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0005" contrib-type="author">
                  <name>
                    <surname>Gupta</surname>
                    <given-names>Kamal</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2440-9033</contrib-id>
                  <xref rid="jah38858-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0006" contrib-type="author">
                  <name>
                    <surname>Farrehi</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1576-7557</contrib-id>
                  <xref rid="jah38858-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0007" contrib-type="author">
                  <name>
                    <surname>Benziger</surname>
                    <given-names>Catherine P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8992-6197</contrib-id>
                  <xref rid="jah38858-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0008" contrib-type="author">
                  <name>
                    <surname>Effron</surname>
                    <given-names>Mark B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4050-5030</contrib-id>
                  <xref rid="jah38858-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0009" contrib-type="author">
                  <name>
                    <surname>Whittle</surname>
                    <given-names>Jeffrey</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9544-838X</contrib-id>
                  <xref rid="jah38858-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0010" contrib-type="author">
                  <name>
                    <surname>Muñoz</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0991-2992</contrib-id>
                  <xref rid="jah38858-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0011" contrib-type="author">
                  <name>
                    <surname>Kripalani</surname>
                    <given-names>Sunil</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4214-7129</contrib-id>
                  <xref rid="jah38858-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0012" contrib-type="author">
                  <name>
                    <surname>Anderson</surname>
                    <given-names>R. David</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3490-3286</contrib-id>
                  <xref rid="jah38858-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0013" contrib-type="author">
                  <name>
                    <surname>Jain</surname>
                    <given-names>Sandeep K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5815-370X</contrib-id>
                  <xref rid="jah38858-aff-0011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0014" contrib-type="author">
                  <name>
                    <surname>Polonsky</surname>
                    <given-names>Tamar S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2112-9244</contrib-id>
                  <xref rid="jah38858-aff-0012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0015" contrib-type="author">
                  <name>
                    <surname>Ahmad</surname>
                    <given-names>Faraz S.</given-names>
                  </name>
                  <degrees>MD, MS</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2613-2541</contrib-id>
                  <xref rid="jah38858-aff-0013" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0016" contrib-type="author">
                  <name>
                    <surname>Roe</surname>
                    <given-names>Matthew T.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="jah38858-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0017" contrib-type="author">
                  <name>
                    <surname>Rothman</surname>
                    <given-names>Russell L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1506-3990</contrib-id>
                  <xref rid="jah38858-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0018" contrib-type="author">
                  <name>
                    <surname>Harrington</surname>
                    <given-names>Robert A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5450-8676</contrib-id>
                  <xref rid="jah38858-aff-0014" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0019" contrib-type="author">
                  <name>
                    <surname>Hernandez</surname>
                    <given-names>Adrian F.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3387-9616</contrib-id>
                  <xref rid="jah38858-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38858-cr-0020" contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>W. Schuyler</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7288-9596</contrib-id>
                  <xref rid="jah38858-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jah38858-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>University of Texas Southwestern Medical Center</institution>
                <city>Dallas</city>
                <named-content content-type="country-part">TX</named-content>
              </aff>
              <aff id="jah38858-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Duke University Medical Center and Duke Clinical Research Institute</institution>
                <city>Durham</city>
                <named-content content-type="country-part">NC</named-content>
              </aff>
              <aff id="jah38858-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Université de Montréal</institution>
                <city>Montreal</city>
                <named-content content-type="country-part">QC</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="jah38858-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>University of Kansas Medical Center</institution>
                <city>Kansas City</city>
                <named-content content-type="country-part">KS</named-content>
              </aff>
              <aff id="jah38858-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>University of Michigan</institution>
                <city>Ann Arbor</city>
                <named-content content-type="country-part">MI</named-content>
              </aff>
              <aff id="jah38858-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>Essentia Health Heart and Vascular Center</institution>
                <city>Duluth</city>
                <named-content content-type="country-part">MN</named-content>
              </aff>
              <aff id="jah38858-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>Ochsner Health</institution>
                <city>New Orleans</city>
                <named-content content-type="country-part">LA</named-content>
              </aff>
              <aff id="jah38858-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <institution>Medical College of Wisconsin</institution>
                <city>Milwaukee</city>
                <named-content content-type="country-part">WI</named-content>
              </aff>
              <aff id="jah38858-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <institution>Vanderbilt University Medical Center</institution>
                <city>Nashville</city>
                <named-content content-type="country-part">TN</named-content>
              </aff>
              <aff id="jah38858-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <institution>University of Florida</institution>
                <city>Gainesville</city>
                <named-content content-type="country-part">FL</named-content>
              </aff>
              <aff id="jah38858-aff-0011">
                <label>
                  <sup>11</sup>
                </label>
                <institution>University of Pittsburg Medical Center</institution>
                <city>Pittsburgh</city>
                <named-content content-type="country-part">PA</named-content>
              </aff>
              <aff id="jah38858-aff-0012">
                <label>
                  <sup>12</sup>
                </label>
                <institution>University of Chicago Medicine</institution>
                <city>Chicago</city>
                <named-content content-type="country-part">IL</named-content>
              </aff>
              <aff id="jah38858-aff-0013">
                <label>
                  <sup>13</sup>
                </label>
                <institution>Northwestern University Feinberg School of Medicine</institution>
                <city>Chicago</city>
                <named-content content-type="country-part">IL</named-content>
              </aff>
              <aff id="jah38858-aff-0014">
                <label>
                  <sup>14</sup>
                </label>
                <institution>Stanford University School of Medicine</institution>
                <city>Stanford</city>
                <named-content content-type="country-part">CA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Saket Girotra, MD, SM, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Suite E5.723, Dallas, TX 75390. Email: <email>saket.girotra@utsouthwestern.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>17</day>
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="100">20</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v12.20</issue-id>
              <elocation-id>e030385</elocation-id>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>06</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-12-e030385.pdf"/>
              <abstract>
                <sec id="jah38858-sec-0001">
                  <title>Background</title>
                  <p>The ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness) was a large, pragmatic, randomized controlled trial that found no difference between high‐ versus low‐dose aspirin for secondary prevention of atherosclerotic cardiovascular disease. Whether concomitant P2Y12 inhibitor therapy modifies the effect of aspirin dose on clinical events remains unclear.</p>
                </sec>
                <sec id="jah38858-sec-0002">
                  <title>Methods and Results</title>
                  <p>Participants in ADAPTABLE were stratified according to baseline use of clopidogrel or prasugrel (P2Y12 group). The primary effectiveness end point was a composite of death, myocardial infarction, or stroke; and the primary safety end point was major bleeding requiring blood transfusions. We used multivariable Cox regression to compare the relative effectiveness and safety of aspirin dose within P2Y12 and non‐P2Y12 groups. Of 13 815 (91.6%) participants with available data, 3051 (22.1%) were receiving clopidogrel (2849 [93.4%]) or prasugrel (203 [6.7%]) at baseline. P2Y12 inhibitor use was associated with higher risk of the primary effectiveness end point (10.86% versus 6.31%; adjusted hazard ratio [HR], 1.40 [95% CI, 1.22–1.62]) but was not associated with bleeding (0.95% versus 0.53%; adjusted HR, 1.42 [95% CI, 0.91–2.22]). We found no interaction in the relative effectiveness and safety of high‐ versus low‐dose aspirin by P2Y12 inhibitor use. Overall, dose switching or discontinuation was more common in the high‐dose compared with low‐dose aspirin group, but the pattern was not modified by P2Y12 inhibitor use.</p>
                </sec>
                <sec id="jah38858-sec-0003">
                  <title>Conclusions</title>
                  <p>In this prespecified analysis of ADAPTABLE, we found that the relative effectiveness and safety of high‐ versus low‐dose aspirin was not modified by baseline P2Y12 inhibitor use.</p>
                </sec>
                <sec id="jah38858-sec-0004">
                  <title>Registration</title>
                  <p><ext-link xlink:href="https://www.clinical.trials.gov" ext-link-type="uri">https://www.clinical.trials.gov</ext-link>. Unique identifier: NCT02697916.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah38858-kwd-0001">aspirin</kwd>
                <kwd id="jah38858-kwd-0002">atherosclerotic cardiovascular disease</kwd>
                <kwd id="jah38858-kwd-0003">secondary prevention</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Cardiovascular Disease</kwd>
              </kwd-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <page-count count="10"/>
                <word-count count="5799"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>17 October 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.6 mode:remove_FC converted:19.12.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="jah38858-ntgp-0001">
                <fn id="jah38858-note-0001">
                  <p>This article was sent to Barry London, MD, PhD, Senior Guest Editor, for review by expert referees, editorial decision, and final disposition.</p>
                </fn>
                <fn id="jah38858-note-0002">
                  <p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.030385" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.030385</ext-link>
</p>
                </fn>
                <fn id="jah38858-note-0003">
                  <p>For Sources of Funding and Disclosures, see page 9.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah38858-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="jah38858-blkfxd-0001">
                <caption>
                  <title>Clinical Perspective</title>
                </caption>
                <sec id="jah38858-sec-0007">
                  <title>What Is New?</title>
                  <p>
                    <list list-type="bullet" id="jah38858-list-0001">
                      <list-item id="jah38858-li-0001">
                        <p>Among participants with established atherosclerotic cardiovascular disease who were also receiving a P2Y12 inhibitor at baseline, there was no significant difference between low‐ versus high‐dose aspirin for the risk of major adverse cardiovascular events and bleeding events.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
                <sec id="jah38858-sec-0008">
                  <title>What Are the Clinical Implications?</title>
                  <p>
                    <list list-type="bullet" id="jah38858-list-0002">
                      <list-item id="jah38858-li-0002">
                        <p>Decisions about aspirin dosing should be individualized based on clinical factors and patient preferences, regardless of P2Y12 inhibitor use.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <def-list list-type="simple" id="jah38858-lp-0001">
                <title>Nonstandard Abbreviations and Acronyms</title>
                <def-item>
                  <term id="jah38858-li-0003">ADAPTABLE</term>
                  <def id="jah38858-li-0004">
                    <p>Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="jah38858-li-0005">MACE</term>
                  <def id="jah38858-li-0006">
                    <p>major adverse cardiovascular event</p>
                  </def>
                </def-item>
              </def-list>
            </p>
            <p>Antiplatelet drugs are the cornerstone of treatment in patients with atherosclerotic cardiovascular disease (ASCVD) and have been shown in multiple randomized controlled trials to reduce the risk of future ischemic events.<xref rid="jah38858-bib-0001" ref-type="bibr"><sup>1</sup></xref> However, there has been controversy about the optimal dose of aspirin for secondary prevention in ASCVD. The ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness) was a phase 3 multicenter randomized controlled trial that compared low‐dose aspirin (81 mg) with high‐dose aspirin (325 mg) and found no overall difference in the risk of major adverse cardiovascular events (MACEs) or bleeding.<xref rid="jah38858-bib-0002" ref-type="bibr"><sup>2</sup></xref> However, it remains unknown whether concomitant therapy with a P2Y12 inhibitor modifies the effect of aspirin dose on future risk of cardiovascular events and major bleeding in a stable population of patients with ASCVD.</p>
            <p>Dual‐antiplatelet therapy, which typically includes oral aspirin and a P2Y12 inhibitor, is commonly prescribed in patients after an acute coronary syndrome and those treated with percutaneous coronary intervention (PCI), as these patients are at a high risk of recurrent thrombotic events.<xref rid="jah38858-bib-0003" ref-type="bibr"><sup>3</sup></xref> By providing additional platelet inhibition, dual‐antiplatelet therapy mitigates the risk of stent thrombosis and reduces the risk of MACEs in such patients.<xref rid="jah38858-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah38858-bib-0005" ref-type="bibr"><sup>5</sup></xref> However, the optimal dose of aspirin in patients also receiving a P2Y12 inhibitor remains unclear.<xref rid="jah38858-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jah38858-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah38858-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jah38858-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="jah38858-bib-0010" ref-type="bibr"><sup>10</sup></xref> Given their potent antiplatelet effects, P2Y12 inhibitors can provide substantial ischemic risk reduction but may lead to higher bleeding risk. Therefore, concomitant therapy with a P2Y12 inhibitor may tip the balance in favor of low‐dose aspirin, especially with regard to reduction in bleeding risk. On the other hand, a need for P2Y12 inhibitor therapy may be representative of patients at increased risk of ischemic events (eg, recent myocardial infarction [MI]), who may benefit from higher‐dose aspirin for ischemic risk reduction. Prior studies of the relative effectiveness of aspirin dosing in patients also receiving P2Y12 inhibitors have been primarily conducted in patients who were discharged from a hospital with acute coronary syndrome.<xref rid="jah38858-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah38858-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="jah38858-bib-0010" ref-type="bibr"><sup>10</sup></xref> The relative effectiveness of high‐ versus low‐dose aspirin in patients taking concomitant P2Y12 inhibitors with stable ASCVD remains less clear.</p>
            <p>To address this gap in knowledge, we conducted a prespecified subgroup analysis of the ADAPTABLE to address whether the relative effectiveness and safety of low‐ versus high‐dose aspirin differs in patients who were also receiving P2Y12 inhibitor at randomization.</p>
            <sec sec-type="methods" id="jah38858-sec-0009">
              <title>Methods</title>
              <p>Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to Dr Schuyler Jones (<email>schuyler.jones@duke.edu</email>) at Duke University.</p>
              <sec id="jah38858-sec-0010">
                <title>Study Design and Population</title>
                <p>The details of the study design have been published previously.<xref rid="jah38858-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="jah38858-bib-0011" ref-type="bibr"><sup>11</sup></xref> Briefly, ADAPTABLE was an open‐label, pragmatic randomized controlled trial that randomized 15 076 patients (40 clinical centers and 1 private health insurance plan) with established ASCVD to 81 versus 325 mg aspirin and compared the risk of MACEs (primary effectiveness end point) and major bleeding events (primary safety end point). Patients were eligible if they had a history of MI, coronary revascularization, coronary angiography demonstrating ≥75% stenosis of at least 1 epicardial coronary artery, or chronic coronary artery disease with a least 1 risk enrichment factor. Current treatment with clopidogrel or prasugrel was permitted, but ticagrelor was not permitted because of the black box warning on use of high‐dose aspirin in combination with ticagrelor.<xref rid="jah38858-bib-0012" ref-type="bibr"><sup>12</sup></xref> Similarly, patients receiving oral anticoagulants (eg, warfarin or direct oral anticoagulants) were also excluded. A computable phenotype query was executed at each site to identify patients eligible for inclusion in the study. Participants were invited to participate in the study using a combination of low‐touch (eg, letters, emails, and telephone calls) and high‐touch (eg, during in‐person visits) approaches. All patients provided electronic informed consent, and the institutional review boards at all participating centers approved the study.</p>
              </sec>
              <sec id="jah38858-sec-0011">
                <title>Study Variables and End Points</title>
                <p>The main study exposure was whether a patient was receiving treatment with a P2Y12 inhibitor (ie, clopidogrel or prasugrel) at the time of randomization, as self‐reported by the participant. Study variables included demographic characteristics, including age, sex, race, ethnic group, current tobacco use, and medication use before randomization (self‐reported by patients). Clinical characteristics and medical history were retrieved by means of a trial‐specific query of the electronic health record with the use of the Patient‐Centered Outcomes Research Network Common Data Model format at enrolling health centers. All baseline variables were recorded with a look‐back period of 5 years from the date of enrollment.</p>
                <p>The primary effectiveness end point was a composite of all‐cause mortality, hospitalization for nonfatal MI, or hospitalization for nonfatal stroke. Secondary end points included the individual components of the primary composite end point (MI, stroke, and all‐cause mortality) and the occurrence of coronary revascularization. The primary safety end point was hospitalization for bleeding requiring blood transfusion. The study end points were ascertained via multiple data sources, including direct contact with patients via either telephone or the online study portal or indirectly through the electronic health record data and public and private insurance claims. After initial enrollment in the study, follow‐up interval was also randomized to occur at 3 or 6 months.</p>
              </sec>
              <sec id="jah38858-sec-0012">
                <title>Statistical Analysis</title>
                <p>The statistical analysis plan was prespecified before conducting the analyses, and all analyses were conducted in the intention‐to‐treat population. Discrete measures are reported as counts and frequencies, and continuous measures are reported as mean and SD. We compared baseline characteristics between study participants who were receiving treatment with a P2Y12 inhibitor (clopidogrel or prasugrel) with patients who were not receiving these drugs, using χ<sup>2</sup> test for categorical variables and <italic toggle="yes">t</italic>‐test or Wilcoxon rank‐sum test for continuous variables. Next, we examined the cumulative incidence of survival over a median follow‐up of 26.2 months using the Kalbfleish and Prentice cumulative incidence function estimator for the P2Y12 inhibitor and the non‐P2Y12 inhibitor group. To evaluate the association of P2Y12 inhibitor use with study end points, we constructed multivariable Cox proportional hazards regression models that adjusted for age, race, ethnicity, prior aspirin use, smoking status, noninternet user at randomization, history of atrial fibrillation, bleeding, coronary artery disease, congestive heart failure, cerebrovascular disease, diabetes, hypertension, hyperlipidemia, prior MI, peripheral artery disease, chronic kidney disease, prior coronary artery bypass grafting, prior PCI, prior gastrointestinal tract bleeding, and prior intracranial hemorrhage. For the secondary effectiveness end points, we used the Fine and Gray method to account for the competing risk of death from any cause. The proportional hazards assumption was assessed using weighted Schoenfeld residuals and was violated for the primary effectiveness end point (death, MI, and stroke) and the secondary end point of MI. To investigate the severity of the violation of the proportional hazards assumption, we separately modeled events before and after the time point at which the violation was observed. Next, we included an interaction term between P2Y12 inhibitor use and the assigned aspirin dose to determine whether the relative effectiveness and safety of low‐ versus high‐dose aspirin differed by use of baseline P2Y12 inhibitors for both the primary effectiveness and safety end points.</p>
                <p>Finally, we also examined adherence to randomized aspirin dose between low‐ versus high‐dose aspirin groups and examined whether these patterns differed by use of P2Y12 inhibitors at baseline. All analyses were performed using SAS software, version 9.4 (SAS Institute, Inc, Cary, NC). Statistical significance was assessed using 2‐sided tests with an overall <italic toggle="yes">P</italic> value of 0.05.</p>
                <p>The study was approved by the Institutional Review Board at each participating institution, and all participants provided informed consent.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah38858-sec-0013">
              <title>Results</title>
              <p>Among 15 076 participants enrolled in ADAPTABLE, data on P2Y12 therapy at baseline were available in 13 815 (91.6%). Among these patients, 3051 (22.1%) were receiving a P2Y12 inhibitor at baseline: clopidogrel (2849 [93.4%]) or prasugrel (203 [6.7%]). Table <xref rid="jah38858-tbl-0001" ref-type="table">1</xref> shows baseline characteristics of study participants. The proportion of patients randomized to low‐ versus high‐dose aspirin was similar between the 2 groups (<italic toggle="yes">P</italic>=0.61). Compared with the non‐P2Y12 group, patients in the P2Y12 group were younger (65.6 versus 67.5 years) and more likely to be of Black race (9.7% versus 8.9%) and Hispanic ethnicity (4.0% versus 3.0%), but they were less likely to be women (27.6% versus 32.0%; <italic toggle="yes">P</italic>&lt;0.0001 for all). Prevalence of smoking, hypertension, hyperlipidemia, congestive heart failure, cerebrovascular disease, chronic kidney disease, diabetes, high body mass index, and history of MI and coronary revascularization was higher in patients in the P2Y12 inhibitor group compared with the non‐P2Y12 inhibitor group (Table <xref rid="jah38858-tbl-0001" ref-type="table">1</xref>). Within both groups, baseline characteristics of participants randomized to low‐ versus high‐dose aspirin were similar (Table <xref rid="jah38858-supitem-0001" ref-type="supplementary-material">S1</xref>).</p>
              <table-wrap position="float" id="jah38858-tbl-0001" content-type="Table">
                <label>Table 1</label>
                <caption>
                  <p>Baseline Characteristics of Study Cohort, Stratified by Use of P2Y12 Inhibitor</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <thead>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="1" colspan="1">Characteristic</th>
                      <th align="left" rowspan="1" colspan="1">All patients (N=13 815)</th>
                      <th align="left" rowspan="1" colspan="1">Reported taking P2Y12 inhibitor (N=3051)</th>
                      <th align="left" rowspan="1" colspan="1">Reported not taking P2Y12 inhibitor (N=10 764)</th>
                      <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Aged ≥65 y</td>
                      <td align="left" rowspan="1" colspan="1">8617 (62.4)</td>
                      <td align="left" rowspan="1" colspan="1">1695 (55.6)</td>
                      <td align="left" rowspan="1" colspan="1">6922 (64.3)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="5" rowspan="1">Randomized dose, mg</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">81</td>
                      <td align="left" rowspan="1" colspan="1">6989 (50.6)</td>
                      <td align="left" rowspan="1" colspan="1">1556 (51.0)</td>
                      <td align="left" rowspan="1" colspan="1">5433 (50.5)</td>
                      <td align="left" rowspan="2" colspan="1">0.6081</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">325</td>
                      <td align="left" rowspan="1" colspan="1">6826 (49.4)</td>
                      <td align="left" rowspan="1" colspan="1">1495 (49.0)</td>
                      <td align="left" rowspan="1" colspan="1">5331 (49.5)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Female sex</td>
                      <td align="left" rowspan="1" colspan="1">4286 (31.0)</td>
                      <td align="left" rowspan="1" colspan="1">842 (27.6)</td>
                      <td align="left" rowspan="1" colspan="1">3444 (32.0)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="5" rowspan="1">Race</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td>
                      <td align="left" rowspan="1" colspan="1">11 475 (83.1)</td>
                      <td align="left" rowspan="1" colspan="1">2477 (81.2)</td>
                      <td align="left" rowspan="1" colspan="1">8998 (83.6)</td>
                      <td align="left" rowspan="7" colspan="1">0.0004</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td>
                      <td align="left" rowspan="1" colspan="1">1256 (9.1)</td>
                      <td align="left" rowspan="1" colspan="1">297 (9.7)</td>
                      <td align="left" rowspan="1" colspan="1">959 (8.9)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td>
                      <td align="left" rowspan="1" colspan="1">138 (1.0)</td>
                      <td align="left" rowspan="1" colspan="1">33 (1.1)</td>
                      <td align="left" rowspan="1" colspan="1">105 (1.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">American Indian/Alaska Native</td>
                      <td align="left" rowspan="1" colspan="1">108 (0.8)</td>
                      <td align="left" rowspan="1" colspan="1">24 (0.8)</td>
                      <td align="left" rowspan="1" colspan="1">84 (0.8)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multiple</td>
                      <td align="left" rowspan="1" colspan="1">129 (0.9)</td>
                      <td align="left" rowspan="1" colspan="1">39 (1.3)</td>
                      <td align="left" rowspan="1" colspan="1">90 (0.8)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                      <td align="left" rowspan="1" colspan="1">362 (2.6)</td>
                      <td align="left" rowspan="1" colspan="1">111 (3.6)</td>
                      <td align="left" rowspan="1" colspan="1">251 (2.3)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prefer not to say/missing</td>
                      <td align="left" rowspan="1" colspan="1">347 (2.5)</td>
                      <td align="left" rowspan="1" colspan="1">70 (2.3)</td>
                      <td align="left" rowspan="1" colspan="1">277 (2.6)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="5" rowspan="1">Ethnicity</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hispanic</td>
                      <td align="left" rowspan="1" colspan="1">451 (3.3)</td>
                      <td align="left" rowspan="1" colspan="1">123 (4.0)</td>
                      <td align="left" rowspan="1" colspan="1">328 (3.0)</td>
                      <td align="left" rowspan="3" colspan="1">0.0250</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non‐Hispanic</td>
                      <td align="left" rowspan="1" colspan="1">12 978 (94.0)</td>
                      <td align="left" rowspan="1" colspan="1">2844 (93.3)</td>
                      <td align="left" rowspan="1" colspan="1">10 134 (94.2)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Did not respond</td>
                      <td align="left" rowspan="1" colspan="1">383 (2.8)</td>
                      <td align="left" rowspan="1" colspan="1">82 (2.7)</td>
                      <td align="left" rowspan="1" colspan="1">301 (2.8)</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Current smoker</td>
                      <td align="left" rowspan="1" colspan="1">1342 (9.7)</td>
                      <td align="left" rowspan="1" colspan="1">380 (12.5)</td>
                      <td align="left" rowspan="1" colspan="1">962 (9.0)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">History of PAD</td>
                      <td align="left" rowspan="1" colspan="1">3242 (24.0)</td>
                      <td align="left" rowspan="1" colspan="1">965 (32.3)</td>
                      <td align="left" rowspan="1" colspan="1">2277 (21.7)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="5" rowspan="1">EHR and claims information</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="5" rowspan="1">BMI, kg/m<sup>2</sup>
</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">No.</td>
                      <td align="left" rowspan="1" colspan="1">11 741</td>
                      <td align="left" rowspan="1" colspan="1">2612</td>
                      <td align="left" rowspan="1" colspan="1">9129</td>
                      <td align="left" rowspan="2" colspan="1">0.0074</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mean±SD</td>
                      <td align="left" rowspan="1" colspan="1">30.9±6.2</td>
                      <td align="left" rowspan="1" colspan="1">31.2±6.0</td>
                      <td align="left" rowspan="1" colspan="1">30.8±6.2</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Atrial fibrillation/flutter</td>
                      <td align="left" rowspan="1" colspan="1">1151 (8.5)</td>
                      <td align="left" rowspan="1" colspan="1">267 (8.9)</td>
                      <td align="left" rowspan="1" colspan="1">884 (8.4)</td>
                      <td align="left" rowspan="1" colspan="1">0.3724</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">History of bleeding</td>
                      <td align="left" rowspan="1" colspan="1">1156 (8.6)</td>
                      <td align="left" rowspan="1" colspan="1">262 (8.8)</td>
                      <td align="left" rowspan="1" colspan="1">894 (8.5)</td>
                      <td align="left" rowspan="1" colspan="1">0.6615</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Significant gastrointestinal tract bleeding</td>
                      <td align="left" rowspan="1" colspan="1">864 (6.4)</td>
                      <td align="left" rowspan="1" colspan="1">184 (6.2)</td>
                      <td align="left" rowspan="1" colspan="1">680 (6.5)</td>
                      <td align="left" rowspan="1" colspan="1">0.5308</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">History of ICH</td>
                      <td align="left" rowspan="1" colspan="1">190 (1.4)</td>
                      <td align="left" rowspan="1" colspan="1">50 (1.7)</td>
                      <td align="left" rowspan="1" colspan="1">140 (1.3)</td>
                      <td align="left" rowspan="1" colspan="1">0.1641</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">History of bleeding disorder</td>
                      <td align="left" rowspan="1" colspan="1">165 (1.2)</td>
                      <td align="left" rowspan="1" colspan="1">41 (1.4)</td>
                      <td align="left" rowspan="1" colspan="1">124 (1.2)</td>
                      <td align="left" rowspan="1" colspan="1">0.4015</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Coronary artery disease</td>
                      <td align="left" rowspan="1" colspan="1">12 653 (93.7)</td>
                      <td align="left" rowspan="1" colspan="1">2910 (97.3)</td>
                      <td align="left" rowspan="1" colspan="1">9743 (92.7)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Congestive heart failure</td>
                      <td align="left" rowspan="1" colspan="1">3186 (23.6)</td>
                      <td align="left" rowspan="1" colspan="1">885 (29.6)</td>
                      <td align="left" rowspan="1" colspan="1">2301 (21.9)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Chronic kidney disease</td>
                      <td align="left" rowspan="1" colspan="1">2464 (18.3)</td>
                      <td align="left" rowspan="1" colspan="1">625 (20.9)</td>
                      <td align="left" rowspan="1" colspan="1">1839 (17.5)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">COPD</td>
                      <td align="left" rowspan="1" colspan="1">2558 (19.0)</td>
                      <td align="left" rowspan="1" colspan="1">584 (19.5)</td>
                      <td align="left" rowspan="1" colspan="1">1974 (18.8)</td>
                      <td align="left" rowspan="1" colspan="1">0.3596</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">CVD</td>
                      <td align="left" rowspan="1" colspan="1">2408 (17.8)</td>
                      <td align="left" rowspan="1" colspan="1">700 (23.4)</td>
                      <td align="left" rowspan="1" colspan="1">1708 (16.3)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Diabetes</td>
                      <td align="left" rowspan="1" colspan="1">5225 (38.7)</td>
                      <td align="left" rowspan="1" colspan="1">1360 (45.5)</td>
                      <td align="left" rowspan="1" colspan="1">3865 (36.8)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Hypertension</td>
                      <td align="left" rowspan="1" colspan="1">11 523 (85.4)</td>
                      <td align="left" rowspan="1" colspan="1">2653 (88.7)</td>
                      <td align="left" rowspan="1" colspan="1">8870 (84.4)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Hyperlipidemia</td>
                      <td align="left" rowspan="1" colspan="1">11 948 (88.5)</td>
                      <td align="left" rowspan="1" colspan="1">2718 (90.9)</td>
                      <td align="left" rowspan="1" colspan="1">9230 (87.8)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Prior MI</td>
                      <td align="left" rowspan="1" colspan="1">4882 (36.2)</td>
                      <td align="left" rowspan="1" colspan="1">1580 (52.8)</td>
                      <td align="left" rowspan="1" colspan="1">3302 (31.4)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Peptic ulcer disease</td>
                      <td align="left" rowspan="1" colspan="1">403 (3.0)</td>
                      <td align="left" rowspan="1" colspan="1">95 (3.2)</td>
                      <td align="left" rowspan="1" colspan="1">308 (2.9)</td>
                      <td align="left" rowspan="1" colspan="1">0.4858</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">PCI/CABG</td>
                      <td align="left" rowspan="1" colspan="1">7384 (54.7)</td>
                      <td align="left" rowspan="1" colspan="1">2347 (78.5)</td>
                      <td align="left" rowspan="1" colspan="1">5037 (47.9)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior CABG</td>
                      <td align="left" rowspan="1" colspan="1">3273 (24.2)</td>
                      <td align="left" rowspan="1" colspan="1">879 (29.4)</td>
                      <td align="left" rowspan="1" colspan="1">2394 (22.8)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PCI</td>
                      <td align="left" rowspan="1" colspan="1">5498 (40.7)</td>
                      <td align="left" rowspan="1" colspan="1">2093 (70.0)</td>
                      <td align="left" rowspan="1" colspan="1">3405 (32.4)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Prior aspirin use</td>
                      <td align="left" rowspan="1" colspan="1">13 250 (96.1)</td>
                      <td align="left" rowspan="1" colspan="1">2964 (97.4)</td>
                      <td align="left" rowspan="1" colspan="1">10 286 (95.7)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="5" rowspan="1">Prior aspirin dose, mg</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">81</td>
                      <td align="left" rowspan="1" colspan="1">11 307 (85.5)</td>
                      <td align="left" rowspan="1" colspan="1">2550 (86.2)</td>
                      <td align="left" rowspan="1" colspan="1">8757 (85.2)</td>
                      <td align="left" rowspan="3" colspan="1">0.0328</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">162</td>
                      <td align="left" rowspan="1" colspan="1">307 (2.3)</td>
                      <td align="left" rowspan="1" colspan="1">50 (1.7)</td>
                      <td align="left" rowspan="1" colspan="1">257 (2.5)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">325</td>
                      <td align="left" rowspan="1" colspan="1">1616 (12.2)</td>
                      <td align="left" rowspan="1" colspan="1">357 (12.1)</td>
                      <td align="left" rowspan="1" colspan="1">1259 (12.3)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah38858-ntgp-0002">
                  <fn id="jah38858-note-0004">
                    <p>Data are given as number (percentage) of each group unless otherwise indicated. BMI indicates body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; EHR, electronic health record; ICH, intracranial hemorrhage; MI, myocardial infarction; PAD, peripheral artery disease; and PCI, percutaneous coronary intervention.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Table <xref rid="jah38858-tbl-0002" ref-type="table">2</xref> includes the overall incidence of study end points in the P2Y12 inhibitor and the non‐P2Y12 inhibitor groups. The cumulative incidence of the primary end point was 10.9% in the P2Y12 group compared with 6.3% in the non‐P2Y12 inhibitor group (Figure <xref rid="jah38858-fig-0001" ref-type="fig">1</xref>), with an adjusted hazard ratio (HR) of 1.40 (95% CI, 1.22–1.62). The difference in the primary end point was largely driven by a higher incidence of MI in the P2Y12 group (5.9% versus 2.3%; adjusted HR, 1.90 [95% CI, 1.53–2.36]), compared with the non‐P2Y12 group. Rate of subsequent PCI or coronary artery bypass grafting was also significantly higher in the P2Y12 group (Table <xref rid="jah38858-tbl-0002" ref-type="table">2</xref>). There was no difference in the incidence of major bleeding between the P2Y12 and the non‐P2Y12 groups (0.95% versus 0.53%; adjusted HR, 1.42 [95% CI, 0.91–2.22]).</p>
              <table-wrap position="float" id="jah38858-tbl-0002" content-type="Table">
                <label>Table 2</label>
                <caption>
                  <p>Cumulative Incidence of Study End Points by P2Y12 Inhibitor at Baseline</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <thead>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">Variable</th>
                      <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">P2Y12 inhibitor use, event (%)</th>
                      <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">No P2Y12 inhibitor use, event (%)</th>
                      <th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Adjusted Cox model</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
                      <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Death/MI/stroke</td>
                      <td align="left" rowspan="1" colspan="1">349 (10.9)</td>
                      <td align="left" rowspan="1" colspan="1">720 (6.3)</td>
                      <td align="left" rowspan="1" colspan="1">1.40 (1.22–1.62)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">All‐cause mortality</td>
                      <td align="left" rowspan="1" colspan="1">169 (4.9)</td>
                      <td align="left" rowspan="1" colspan="1">443 (3.7)</td>
                      <td align="left" rowspan="1" colspan="1">1.10 (0.90–1.35)</td>
                      <td align="left" rowspan="1" colspan="1">0.339</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">MI</td>
                      <td align="left" rowspan="1" colspan="1">173 (5.9)</td>
                      <td align="left" rowspan="1" colspan="1">244 (2.3)</td>
                      <td align="left" rowspan="1" colspan="1">1.90 (1.53–2.36)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Stroke</td>
                      <td align="left" rowspan="1" colspan="1">57 (1.7)</td>
                      <td align="left" rowspan="1" colspan="1">118 (1.1)</td>
                      <td align="left" rowspan="1" colspan="1">1.40 (1.01–1.94)</td>
                      <td align="left" rowspan="1" colspan="1">0.042</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Major bleeding</td>
                      <td align="left" rowspan="1" colspan="1">32 (1.0)</td>
                      <td align="left" rowspan="1" colspan="1">58 (0.5)</td>
                      <td align="left" rowspan="1" colspan="1">1.42 (0.91–2.22)</td>
                      <td align="left" rowspan="1" colspan="1">0.121</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">PCI or CABG</td>
                      <td align="left" rowspan="1" colspan="1">389 (12.9)</td>
                      <td align="left" rowspan="1" colspan="1">467 (4.3)</td>
                      <td align="left" rowspan="1" colspan="1">2.23 (1.92–2.58)</td>
                      <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah38858-ntgp-0003">
                  <fn id="jah38858-note-0005">
                    <p>Cumulative incidence is reported at 26.2 months from randomization (the median follow‐up time for all‐cause mortality).</p>
                  </fn>
                  <fn id="jah38858-note-0006">
                    <p>Adjustment variables include age, ethnicity, race, prior aspirin use, smoking status, no internet, history of atrial fibrillation, bleeding, coronary artery disease, congestive heart failure, cerebrovascular disease, diabetes, hypertension, hyperlipidemia, prior MI, peripheral artery disease, prior CABG, prior PCI, significant gastrointestinal tract bleeding, prior intracranial hemorrhage, and chronic kidney disease.</p>
                  </fn>
                  <fn id="jah38858-note-0007">
                    <p>CABG indicates coronary artery bypass grafting; HR, hazard ratio; MI, myocardial infarction; and PCI, percutaneous coronary intervention.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig position="float" fig-type="Figure" id="jah38858-fig-0001">
                <label>Figure 1</label>
                <caption>
                  <title>Cumulative incidence function curves for all‐cause mortality, hospitalization for nonfatal myocardial infarction (MI), and hospitalization for stroke.</title>
                  <p>The figure displays the cumulative incidence function curves for the primary end point for participants in the P2Y12 group (blue line) and the non‐P2Y12 group (red line).</p>
                </caption>
                <graphic xlink:href="JAH3-12-e030385-g001" position="anchor" id="jats-graphic-1"/>
              </fig>
              <p>In the intention‐to‐treat analysis, the relative effectiveness of high‐ versus low‐dose aspirin was not modified by baseline P2Y12 inhibitor use (Table <xref rid="jah38858-tbl-0003" ref-type="table">3</xref> and Figure <xref rid="jah38858-fig-0002" ref-type="fig">2</xref>). In the P2Y12 group, the incidence of primary end point was 11.5% in patients randomized to 81 mg aspirin and 10.2% in patients randomized to 325 mg aspirin (adjusted HR, 1.21 [95% CI, 0.97–1.50]). In the non‐P2Y12 group, the incidence of primary end point was 6.0% in the 81 mg aspirin group versus 6.7% in the high‐dose aspirin group (adjusted HR, 0.96 [95% CI, 0.83–1.12]; <italic toggle="yes">P</italic> value for interaction=0.093). Similarly, the relative safety of low‐ versus high‐dose aspirin did not differ by baseline P2Y12 inhibitor use (<italic toggle="yes">P</italic> value for interaction=0.726).</p>
              <table-wrap position="float" id="jah38858-tbl-0003" content-type="Table">
                <label>Table 3</label>
                <caption>
                  <p>Cumulative Incidence of Study End Points by Baseline P2Y12 Use and Randomized Aspirin Dose With Cox Proportional Hazard Modeling Results</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <thead>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" colspan="1">Variable</th>
                      <th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">P2Y12 inhibitor use</th>
                      <th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">No P2Y12 inhibitor use</th>
                      <th align="left" style="border-bottom:solid 1px #000000" rowspan="1" colspan="1">Adjusted model interaction <italic toggle="yes">P</italic> value</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="1" colspan="1">81 mg, N (%)</th>
                      <th align="left" rowspan="1" colspan="1">325 mg, N (%)</th>
                      <th align="left" rowspan="1" colspan="1">Adjusted HR (95% CI)</th>
                      <th align="left" rowspan="1" colspan="1">81 mg, N (%)</th>
                      <th align="left" rowspan="1" colspan="1">325 mg, N (%)</th>
                      <th align="left" rowspan="1" colspan="1">Adjusted HR (95% CI)</th>
                      <th align="left" rowspan="1" colspan="1"/>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Primary end point (death, MI, or stroke)</td>
                      <td align="left" rowspan="1" colspan="1">188 (11.5)</td>
                      <td align="left" rowspan="1" colspan="1">161 (10.2)</td>
                      <td align="left" rowspan="1" colspan="1">1.21 (0.97–1.50)</td>
                      <td align="left" rowspan="1" colspan="1">359 (6.0)</td>
                      <td align="left" rowspan="1" colspan="1">361 (6.7)</td>
                      <td align="left" rowspan="1" colspan="1">0.96 (0.83–1.12)</td>
                      <td align="left" rowspan="1" colspan="1">0.093</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">All‐cause mortality</td>
                      <td align="left" rowspan="1" colspan="1">85 (5.1)</td>
                      <td align="left" rowspan="1" colspan="1">84 (4.6)</td>
                      <td align="left" rowspan="1" colspan="1">1.05 (0.77–1.43)</td>
                      <td align="left" rowspan="1" colspan="1">206 (3.3)</td>
                      <td align="left" rowspan="1" colspan="1">237 (4.1)</td>
                      <td align="left" rowspan="1" colspan="1">0.86 (0.71–1.04)</td>
                      <td align="left" rowspan="1" colspan="1">0.289</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">MI</td>
                      <td align="left" rowspan="1" colspan="1">92 (5.9)</td>
                      <td align="left" rowspan="1" colspan="1">81 (5.6)</td>
                      <td align="left" rowspan="1" colspan="1">1.17 (0.86–1.59)</td>
                      <td align="left" rowspan="1" colspan="1">124 (2.2)</td>
                      <td align="left" rowspan="1" colspan="1">120 (2.3)</td>
                      <td align="left" rowspan="1" colspan="1">0.99 (0.76–1.28)</td>
                      <td align="left" rowspan="1" colspan="1">0.401</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Stroke</td>
                      <td align="left" rowspan="1" colspan="1">33 (1.9)</td>
                      <td align="left" rowspan="1" colspan="1">24 (1.6)</td>
                      <td align="left" rowspan="1" colspan="1">1.32 (0.77–2.24)</td>
                      <td align="left" rowspan="1" colspan="1">60 (1.0)</td>
                      <td align="left" rowspan="1" colspan="1">58 (1.1)</td>
                      <td align="left" rowspan="1" colspan="1">0.96 (0.66–1.40)</td>
                      <td align="left" rowspan="1" colspan="1">0.346</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Revascularization</td>
                      <td align="left" rowspan="1" colspan="1">201 (12.9)</td>
                      <td align="left" rowspan="1" colspan="1">188 (12.5)</td>
                      <td align="left" rowspan="1" colspan="1">1.05 (0.86–1.28)</td>
                      <td align="left" rowspan="1" colspan="1">246 (4.3)</td>
                      <td align="left" rowspan="1" colspan="1">221 (4.1)</td>
                      <td align="left" rowspan="1" colspan="1">1.06 (0.88–1.27)</td>
                      <td align="left" rowspan="1" colspan="1">0.944</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">
                        <p>Primary safety end point</p>
                        <p>(major bleeding)</p>
                      </td>
                      <td align="left" rowspan="1" colspan="1">16 (1.0)</td>
                      <td align="left" rowspan="1" colspan="1">16 (0.9)</td>
                      <td align="left" rowspan="1" colspan="1">1.10 (0.54–2.25)</td>
                      <td align="left" rowspan="1" colspan="1">33 (0.5)</td>
                      <td align="left" rowspan="1" colspan="1">25 (0.5)</td>
                      <td align="left" rowspan="1" colspan="1">1.29 (0.76–2.19)</td>
                      <td align="left" rowspan="1" colspan="1">0.726</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah38858-ntgp-0004">
                  <fn id="jah38858-note-0008">
                    <p>Cumulative incidence of study end points in those taking P2Y12 inhibitor at baseline and not taking P2Y12 inhibitor at baseline at 26.2 months after randomization, the median follow‐up time for all‐cause mortality in ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness). HRs represent the relative hazard in the 81‐ vs 325‐mg group.</p>
                  </fn>
                  <fn id="jah38858-note-0009">
                    <p>The farthest column to the right reports adjusted models, including the interaction of P2Y12 and randomized aspirin dose. P2Y12 is not shown to modify the association between randomized aspirin dose and any of the prespecified end points (<italic toggle="yes">P</italic>&gt;0.05 for all).</p>
                  </fn>
                  <fn id="jah38858-note-0010">
                    <p>Adjustment variables include age, ethnicity, race, prior aspirin use, smoking status, no internet, history of atrial fibrillation, bleeding, coronary artery disease, congestive heart failure, cerebrovascular disease, diabetes, hypertension, hyperlipidemia, prior MI, peripheral artery disease, prior coronary artery bypass grafting, prior percutaneous coronary intervention, significant gastrointestinal tract bleeding, prior intracranial hemorrhage, and chronic kidney disease.</p>
                  </fn>
                  <fn id="jah38858-note-0011">
                    <p>HR indicates hazard ratio; and MI, myocardial infarction.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig position="float" fig-type="Figure" id="jah38858-fig-0002">
                <label>Figure 2</label>
                <caption>
                  <title>Cumulative incidence function curves for all‐cause mortality, hospitalization for nonfatal myocardial infarction (MI), and hospitalization for stroke, stratified by randomized aspirin dose.</title>
                  <p>The figure displays the cumulative incidence function curves for the primary end point for participants in the P2Y12 group receiving low‐dose aspirin (solid blue line) and high‐dose aspirin (dashed blue line), and in the non‐P2Y12 group receiving low‐dose aspirin (solid red line) and high‐dose aspirin (dashed red line).</p>
                </caption>
                <graphic xlink:href="JAH3-12-e030385-g002" position="anchor" id="jats-graphic-3"/>
              </fig>
              <p>Schoenfeld residuals for P2Y12 group are plotted against time for the primary end point model (Figure <xref rid="jah38858-supitem-0002" ref-type="supplementary-material">S1</xref>) and the MI model (Figure <xref rid="jah38858-supitem-0002" ref-type="supplementary-material">S2</xref>). Both figures indicate violations of the proportional hazards assumption at 40 months. In sensitivity analyses, we examined the impact of the violation on our study findings. For the primary end point, the violation of the proportional hazards assumption was likely explained by a small number of events in the no P2Y12 group after 40 months of follow‐up (Table <xref rid="jah38858-supitem-0001" ref-type="supplementary-material">S2</xref>). For the secondary end point of MI, although the hazards were no longer parallel after 40 months, the HRs for events with the inclusion of the 2 time‐dependent measures were consistent with the overall measure, suggesting that the violation did not impact the interpretation of the results (Table <xref rid="jah38858-supitem-0001" ref-type="supplementary-material">S3</xref>).</p>
              <p>The incidence of dose switching or treatment discontinuation was higher in patients randomized to high‐dose aspirin compared with low‐dose aspirin group (Table <xref rid="jah38858-tbl-0004" ref-type="table">4</xref>). In the P2Y12 group, 706 (39.3%) in the high‐dose aspirin group discontinued aspirin or switched to low‐dose aspirin, whereas 196 (8.3%) patients in the low‐dose aspirin group discontinued aspirin or switched from low‐ to high‐dose aspirin. In the non‐P2Y12 group, 2360 (38.1%) patients in the high‐dose aspirin group discontinued aspirin or switched from high‐ to low‐dose aspirin, and 687 (8.2%) in the low‐dose aspirin group discontinued aspirin or switched from low‐ to high‐dose aspirin. We found no evidence that pattern of dose switching and treatment discontinuation differed by baseline use of P2Y12 inhibitors.</p>
              <table-wrap position="float" id="jah38858-tbl-0004" content-type="Table">
                <label>Table 4</label>
                <caption>
                  <p>Adherence to Randomized Aspirin Dose, Stratified by Baseline Use of P2Y12 Inhibitors</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <col align="left" span="1"/>
                  <thead>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="1" colspan="1">Variable</th>
                      <th align="left" rowspan="1" colspan="1">Taking P2Y12 inhibitor</th>
                      <th align="left" rowspan="1" colspan="1">Not taking P2Y12 inhibitor</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" colspan="3" rowspan="1">Aspirin dose switching or discontinuation</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">81‐mg Aspirin, N (%)</td>
                      <td align="left" rowspan="1" colspan="1">196 (8.34)</td>
                      <td align="left" rowspan="1" colspan="1">687 (8.21)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">325‐mg Aspirin, N (%)</td>
                      <td align="left" rowspan="1" colspan="1">706 (39.26)</td>
                      <td align="left" rowspan="1" colspan="1">2360 (38.06)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="3" rowspan="1">Aspirin discontinuation</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">81‐mg Aspirin, N (%)</td>
                      <td align="left" rowspan="1" colspan="1">95 (3.86)</td>
                      <td align="left" rowspan="1" colspan="1">360 (4.13)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">325‐mg Aspirin, N (%)</td>
                      <td align="left" rowspan="1" colspan="1">134 (5.49)</td>
                      <td align="left" rowspan="1" colspan="1">563 (6.90)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="3" rowspan="1">Dose switching</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">81‐mg Aspirin, N (%)</td>
                      <td align="left" rowspan="1" colspan="1">107 (4.55)</td>
                      <td align="left" rowspan="1" colspan="1">340 (4.06)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">325‐mg Aspirin, N (%)</td>
                      <td align="left" rowspan="1" colspan="1">602 (33.47)</td>
                      <td align="left" rowspan="1" colspan="1">1938 (31.26)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah38858-ntgp-0005">
                  <fn id="jah38858-note-0012">
                    <p>Dose switching or discontinuation of aspirin occurred when a participant reported a dose different from randomized dose, reported discontinuation of aspirin (permanent or temporary), or never reported aspirin information during follow‐up (missing visits after randomization). Because patients who had discontinued aspirin were no longer at risk for switching, they were excluded from the denominator in calculating rates of dose switching. Switching dose or discontinuing before withdrawal of consent was counted as a dose switch or discontinuation event.</p>
                  </fn>
                  <fn id="jah38858-note-0013">
                    <p>The end of study visit was excluded from defining dose switching and discontinuation because an observed spike in reports of dose switching at the end of study visit seemed to reflect participants' intended dose after trial participation.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
            <sec sec-type="discussion" id="jah38858-sec-0014">
              <title>Discussion</title>
              <p>In this prespecified subgroup analysis of a large, pragmatic, randomized, open‐label trial, we found no difference in the relative effectiveness and safety of high‐ versus low‐dose aspirin in patients receiving treatment with a P2Y12 inhibitor at baseline. Although aspirin dose switching and discontinuation occurred more often in the high‐dose aspirin group, this pattern was not different between the P2Y12 subgroups. Given the overall null findings, decisions about aspirin dosing should be individualized based on clinical factors and patient preference, regardless of P2Y12 inhibitor use.</p>
              <p>Although participants receiving P2Y12 inhibitors were younger, history of prior MI, revascularization, and other cardiovascular and noncardiovascular comorbidities were significantly higher in this subgroup. Use of P2Y12 inhibitors at baseline was associated with a 40% increased risk of the primary effectiveness end point, largely driven by a nearly 2‐fold increase in risk of MI. Although not statistically significant, risk of major bleeding was also numerically higher in the P2Y12 inhibitor group, which suggests that this group represented those at a higher risk for both MACEs and bleeding events. Despite these differences, we found no evidence that the relative effectiveness of high‐ versus low‐dose aspirin differed in patients who were receiving concomitant P2Y12 inhibitor at randomization.</p>
              <p>Previous studies have compared different aspirin doses among patients receiving P2Y12 inhibitors. The CURRENT‐OASIS (Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events−Seventh Organization to Assess Strategies in Ischemic Syndromes) 7 was a large trial that randomized patients with acute coronary syndrome undergoing PCI to high‐ versus low‐dose aspirin and high‐ versus low‐dose clopidogrel in a 2×2 factorial design.<xref rid="jah38858-bib-0008" ref-type="bibr"><sup>8</sup></xref> Overall, there was no difference between high‐ versus low‐dose aspirin with regard to the primary outcome of cardiovascular death, MI, and stroke or major bleeding at 30 days. Although there was a nominally significant interaction between high‐dose aspirin with double‐dose clopidogrel in the CURRENT‐OASIS 7 trial, the <italic toggle="yes">P</italic> value for interaction did not meet the prespecified trial threshold of 0.01, suggesting that the interaction may have been attributable to chance. Similarly, in a secondary analysis of the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) trial, Peters et al found that the relative efficacy of clopidogrel versus placebo in preventing ischemic events was consistent between patients receiving low‐dose (&lt;100 mg), medium‐dose (100–199 mg), and high‐dose (≥200 mg) aspirin, but the risk of bleeding increased with higher dose of aspirin.<xref rid="jah38858-bib-0010" ref-type="bibr"><sup>10</sup></xref> However, both of these studies included patients with acute coronary syndrome, and aspirin dose was not randomized in the CURE trial. Moreover, follow‐up in the CURRENT‐OASIS 7 trial was limited at 30 days.</p>
              <p>In contrast, our study includes a broader population of stable patients with ASCVD who were randomized to low‐ versus high‐dose aspirin therapy. Although we found that the risk of MACEs was higher in patients receiving P2Y12 inhibitor at baseline, we found no signal in favor of either high‐ or low‐dose aspirin in the intention‐to‐treat analysis. The overall negative findings of our study are also consistent with emerging data from randomized controlled trials that have found that, compared with dual‐antiplatelet therapy with aspirin and a P2Y12 inhibitor, discontinuation of aspirin after 1 to 3 months, followed by monotherapy with a P2Y12 inhibitor, does not increase the risk of ischemic events but reduces the risk of bleeding complications.<xref rid="jah38858-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jah38858-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="jah38858-bib-0015" ref-type="bibr"><sup>15</sup></xref> These trials question the continued need for aspirin among patients who have undergone PCI and may explain why we found no signal in favor of either dose of aspirin.</p>
              <p>There was a high rate of dose switching and treatment discontinuation in our study, which occurred more often in patients randomized to high‐dose aspirin compared with low‐dose aspirin. This may have been driven in part by the publication of the 2016 American College of Cardiology and American Heart Association focused update on the duration of dual‐antiplatelet therapy in patients with coronary artery disease, while recruitment in ADAPTABLE was still ongoing.<xref rid="jah38858-bib-0003" ref-type="bibr"><sup>3</sup></xref> In this focused update, low‐dose aspirin received a class I recommendation for secondary prevention, especially in patients receiving a P2Y12 inhibitor. Although the guidelines acknowledged that the recommendation was based on moderate‐quality evidence from nonrandomized studies and that the ongoing ADAPTABLE will provide additional evidence on this question, the strong recommendation in favor of low‐dose aspirin may have contributed to a higher rate of dose switching and treatment discontinuation in patients randomized to high‐dose aspirin. However, the higher rate of dose switching and treatment discontinuation in patients receiving high‐ versus low‐dose aspirin was similar regardless of whether patients were also receiving treatment with a P2Y12 inhibitor.</p>
              <p>It is also important to highlight that ADAPTABLE was a large demonstration project for pragmatic randomized controlled trials within the Patient‐Centered Outcomes Research Network. The trial used novel electronic methods to identify and recruit a large and diverse group of participants with ASCVD, streamlined informed consent and randomization, and leveraged data collected in the electronic health record, public and private insurance claims, and self‐reported data from patients for identifying clinical events. Although the pragmatic design enabled us to achieve efficiency, it also provided important lessons that have implications for future design of pragmatic trials. In particular, there was substantial crossover and dose switching, which likely occurred because of the shifting equipoise between low‐ versus high‐dose aspirin. However, it remains unknown whether closer follow‐up, similar to a traditional trial, would have avoided this.</p>
              <p>Our findings should be interpreted in the context of the following limitations. First, although patients were randomized to low‐ versus high‐dose aspirin, randomization was not stratified by baseline use of P2Y12 therapy. Second, dose and treatment with aspirin was self‐reported by patients. Although adherence to randomized aspirin dose was assessed at follow‐up visits, P2Y12 inhibitor dosing and adherence were not assessed. Moreover, data on time since P2Y12 inhibitor therapy, which may be an important determinant of risk of future events, were not captured. Because of randomization, we expect that time since qualifying ASCVD and initiation of P2Y12 inhibitor therapy should be equally distributed between participants randomized to low‐ versus high‐dose aspirin, and therefore, analyses comparing the relative effectiveness of low‐ versus high‐dose aspirin within P2Y12 inhibitor groups should not be biased. Third, a vast majority of patients (93.3%) received clopidogrel as the P2Y12 inhibitor, and patients with ticagrelor were excluded from the study, which precluded our ability to examine whether the findings differed by type of P2Y12 inhibitor. Fourth, the overall negative findings of our study may have been attributable to the high rate of dose switching and discontinuation in the high‐dose aspirin group, which may have limited our ability to find a significant interaction of aspirin effect by P2Y12 inhibitor use. Fifth, we used a combination of patient self‐report, electronic health record, and claims data to identify study end points, and these end points were validated when compared with a manual chart review.<xref rid="jah38858-bib-0016" ref-type="bibr"><sup>16</sup></xref> However, bleeding events only included hospitalizations that were accompanied by a blood transfusion. Therefore, we are unable to determine whether concomitant use of a P2Y12 inhibitor modifies the effect of different aspirin doses on less severe bleeding events or serious bleeding events that may not result in a blood transfusion. Finally, despite our attempts to enroll a diverse population, the enrollment of women and underrepresented minority groups was lower, which may limit applicability of our findings to a broader population.</p>
              <p>In this prespecified subgroup analysis of a large, pragmatic trial, we found that the relative effectiveness and safety of high‐ versus low‐dose aspirin was not modified by baseline use of P2Y12 inhibitors in patients with established ASCVD. Decisions about aspirin dosing should be individualized based on clinical factors and patient preference, regardless of P2Y12 inhibitor use.</p>
            </sec>
            <sec id="jah38858-sec-0015">
              <title>Sources of Funding</title>
              <p>Dr Girotra is supported by the National Heart, Lung, and Blood Institute (NHLBI; 1R01HL160734, 1R01HL166305, and R56HL158803). Dr Ahmad is supported by grants from the NHLBI (K23HL155970) and the American Heart Association (number 856917).</p>
            </sec>
            <sec id="jah38858-sec-0016">
              <title>Disclosures</title>
              <p>Dr Girotra receives funding from the American Heart Association for editorial work. Dr Marquis‐Gravel reports compensation for consultant services from Cardiovascular Systems Inc, Canadian Heart Research Center, KYE, Novartis, Pfizer, JAMP Pharma, HLS Ther, and Bristol‐Myers Squibb Canada, Bayer, Pendophar, Boston Scientific Corporation, and Amgen Canada. Dr. Marquis‐Gravel also receives compensation from Novartis for other services and grants from Bayer. Dr Effron reports compensation from Eli Lilly and Company for other services and stock holdings in Eli Lilly and Company. Dr Whittle reports grants from Patient‐Centered Outcomes Research Institute and employment by US Department of Veterans Affairs. Dr Jain reports grants from Boston Scientific Corporation and grants from Medtronic USA, Inc. Dr Roe reports stock holdings in AstraZeneca; compensation from F. Hoffmann‐La Roche for data and safety monitoring services; stock options in Verana Health; employment by AstraZeneca; compensation from Novo Nordisk for end point review committee services; and compensation from Regeneron Pharmaceuticals, Inc for data and safety monitoring services. Dr Rothman reports grants from Patient‐Centered Outcomes Research Institute. Dr Harrington reports grants from The Medicines Company; service as Board of Directors for Cytokinetics; grants from Janssen Global Services, LLC; grants from AstraZeneca; employment by Robert A Harrington; and compensation from Bristol‐Myers Squibb for consultant services. Dr Hernandez reports grants from Intellia Therapeutics; compensation from Prolaio for consultant services; grants from Bayer; compensation from Eli Lilly and Company for consultant services; compensation from Novo Nordisk for consultant services; employment by Duke Clinical Research Institute; compensation from Intercept Pharmaceuticals, Inc, for data and safety monitoring services; grants from Boehringer Ingelheim; compensation from CSL Behring for consultant services; compensation from Boehringer Ingelheim for consultant services; compensation from Amgen for consultant services; compensation from Novartis for consultant services; grants from Verily; compensation from Merck for consultant services; grants from American Regent; compensation from AstraZeneca for consultant services; compensation from Eidos for data and safety monitoring services; compensation from Cytokinetics for consultant services; grants from Novo Nordisk Inc; grants from Novartis; grants from Merck; compensation from Bayer for consultant services; grants from AstraZeneca; compensation from Boston Scientific Corporation for consultant services; and compensation from Intellia Therapeutics for consultant services. Dr Jones reports grants from Bayer. The remaining authors have no disclosures to report.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jah38858-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>Tables S1–S3</p>
                </caption>
                <media xlink:href="JAH3-12-e030385-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="jah38858-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p>Figures S1–S2</p>
                </caption>
                <media xlink:href="JAH3-12-e030385-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list content-type="cited-references" id="jah38858-bibl-0001">
              <title>REFERENCES</title>
              <ref id="jah38858-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0001"><string-name><surname>Fihn</surname><given-names>SD</given-names></string-name>, <string-name><surname>Blankenship</surname><given-names>JC</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>KP</given-names></string-name>, <string-name><surname>Bittl</surname><given-names>JA</given-names></string-name>, <string-name><surname>Byrne</surname><given-names>JG</given-names></string-name>, <string-name><surname>Fletcher</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Lange</surname><given-names>RA</given-names></string-name>, <string-name><surname>Levine</surname><given-names>GN</given-names></string-name>, <string-name><surname>Maddox</surname><given-names>TM</given-names></string-name>, et al. <article-title>2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>130</volume>:<fpage>1749</fpage>–<lpage>1767</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000095</pub-id>
<pub-id pub-id-type="pmid">25070666</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0002"><string-name><surname>Jones</surname><given-names>WS</given-names></string-name>, <string-name><surname>Mulder</surname><given-names>H</given-names></string-name>, <string-name><surname>Wruck</surname><given-names>LM</given-names></string-name>, <string-name><surname>Pencina</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Kripalani</surname><given-names>S</given-names></string-name>, <string-name><surname>Munoz</surname><given-names>D</given-names></string-name>, <string-name><surname>Crenshaw</surname><given-names>DL</given-names></string-name>, <string-name><surname>Effron</surname><given-names>MB</given-names></string-name>, <string-name><surname>Re</surname><given-names>RN</given-names></string-name>, <string-name><surname>Gupta</surname><given-names>K</given-names></string-name>, et al. <article-title>Comparative effectiveness of aspirin dosing in cardiovascular disease</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>:<fpage>1981</fpage>–<lpage>1990</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2102137</pub-id>
<pub-id pub-id-type="pmid">33999548</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0003"><string-name><surname>Levine</surname><given-names>GN</given-names></string-name>, <string-name><surname>Bates</surname><given-names>ER</given-names></string-name>, <string-name><surname>Bittl</surname><given-names>JA</given-names></string-name>, <string-name><surname>Brindis</surname><given-names>RG</given-names></string-name>, <string-name><surname>Fihn</surname><given-names>SD</given-names></string-name>, <string-name><surname>Fleisher</surname><given-names>LA</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Lange</surname><given-names>RA</given-names></string-name>, <string-name><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, et al. <article-title>2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST‐elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non‐ST‐elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>134</volume>:<fpage>e123</fpage>–<lpage>e155</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000404</pub-id>
<pub-id pub-id-type="pmid">27026020</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0004"><string-name><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>PW</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KA</given-names></string-name>, <string-name><surname>White</surname><given-names>HD</given-names></string-name>, <string-name><surname>Prabhakaran</surname><given-names>D</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>SG</given-names></string-name>, <string-name><surname>Cornel</surname><given-names>JH</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Clemmensen</surname><given-names>P</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>F</given-names></string-name>, et al. <article-title>Prasugrel versus clopidogrel for acute coronary syndromes without revascularization</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>:<fpage>1297</fpage>–<lpage>1309</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1205512</pub-id>
<pub-id pub-id-type="pmid">22920930</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0005"><string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>SR</given-names></string-name>, <string-name><surname>Chrolavicius</surname><given-names>S</given-names></string-name>, <string-name><surname>Tognoni</surname><given-names>G</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KK</given-names></string-name>. <article-title>Clopidogrel in unstable angina to prevent recurrent events trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>:<fpage>494</fpage>–<lpage>502</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa010746</pub-id>
<pub-id pub-id-type="pmid">11519503</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0006"><string-name><surname>Hall</surname><given-names>HM</given-names></string-name>, <string-name><surname>de Lemos</surname><given-names>JA</given-names></string-name>, <string-name><surname>Enriquez</surname><given-names>JR</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>DK</given-names></string-name>, <string-name><surname>Peng</surname><given-names>SA</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>KP</given-names></string-name>, <string-name><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name><surname>Desai</surname><given-names>N</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Das</surname><given-names>SR</given-names></string-name>. <article-title>Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR)</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2014</year>;<volume>7</volume>:<fpage>701</fpage>–<lpage>707</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.113.000822</pub-id>
<pub-id pub-id-type="pmid">25116897</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0007"><string-name><surname>Kohli</surname><given-names>P</given-names></string-name>, <string-name><surname>Udell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>SA</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>CP</given-names></string-name>, <string-name><surname>Antman</surname><given-names>EM</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>. <article-title>Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON‐TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel‐thrombolysis in myocardial infarction 38)</article-title>. <source>J Am Coll Cardiol.</source><year>2014</year>;<volume>63</volume>:<fpage>225</fpage>–<lpage>232</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2013.09.023</pub-id>
<pub-id pub-id-type="pmid">24140678</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0008"><string-name><surname>Mehta</surname><given-names>SR</given-names></string-name>, <string-name><surname>Bassand</surname><given-names>JP</given-names></string-name>, <string-name><surname>Chrolavicius</surname><given-names>S</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name><surname>Eikelboom</surname><given-names>JW</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KA</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Jolly</surname><given-names>S</given-names></string-name>, <string-name><surname>Joyner</surname><given-names>CD</given-names></string-name>, <string-name><surname>Rupprecht</surname><given-names>HJ</given-names></string-name>, et al. <article-title>Dose comparisons of clopidogrel and aspirin in acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>930</fpage>–<lpage>942</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa0909475</pub-id>
<pub-id pub-id-type="pmid">20818903</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0009"><string-name><surname>Xian</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>TY</given-names></string-name>, <string-name><surname>McCoy</surname><given-names>LA</given-names></string-name>, <string-name><surname>Effron</surname><given-names>MB</given-names></string-name>, <string-name><surname>Henry</surname><given-names>TD</given-names></string-name>, <string-name><surname>Bach</surname><given-names>RG</given-names></string-name>, <string-name><surname>Zettler</surname><given-names>ME</given-names></string-name>, <string-name><surname>Baker</surname><given-names>BA</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>ED</given-names></string-name>. <article-title>Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE‐ACS) study</article-title>. <source>Circulation</source>. <year>2015</year>;<volume>132</volume>:<fpage>174</fpage>–<lpage>181</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.014992</pub-id>
<pub-id pub-id-type="pmid">25995313</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0010"><string-name><surname>Peters</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>SR</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KA</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>BS</given-names></string-name>, <string-name><surname>Kopecky</surname><given-names>SL</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name><surname>Commerford</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Valentin</surname><given-names>V</given-names></string-name>, <string-name><surname>Yusuf</surname><given-names>S</given-names></string-name>, et al. <article-title>Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>:<fpage>1682</fpage>–<lpage>1687</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.CIR.0000091201.39590.CB</pub-id>
<pub-id pub-id-type="pmid">14504182</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0011"><string-name><surname>Marquis‐Gravel</surname><given-names>G</given-names></string-name>, <string-name><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>HR</given-names></string-name>, <string-name><surname>Harrington</surname><given-names>RA</given-names></string-name>, <string-name><surname>Pencina</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Berdan</surname><given-names>LG</given-names></string-name>, <string-name><surname>Hammill</surname><given-names>BG</given-names></string-name>, <string-name><surname>Faulkner</surname><given-names>M</given-names></string-name>, <string-name><surname>Munoz</surname><given-names>D</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, et al. <article-title>Rationale and design of the Aspirin Dosing‐a Patient‐centric Trial Assessing Benefits and Long‐term Effectiveness (ADAPTABLE) trial</article-title>. <source>JAMA Cardiol</source>. <year>2020</year>;<volume>5</volume>:<fpage>598</fpage>–<lpage>607</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamacardio.2020.0116</pub-id>
<pub-id pub-id-type="pmid">32186653</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0012"><string-name><surname>Mahaffey</surname><given-names>KW</given-names></string-name>, <string-name><surname>Wojdyla</surname><given-names>DM</given-names></string-name>, <string-name><surname>Carroll</surname><given-names>K</given-names></string-name>, <string-name><surname>Becker</surname><given-names>RC</given-names></string-name>, <string-name><surname>Storey</surname><given-names>RF</given-names></string-name>, <string-name><surname>Angiolillo</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Held</surname><given-names>C</given-names></string-name>, <string-name><surname>Cannon</surname><given-names>CP</given-names></string-name>, <string-name><surname>James</surname><given-names>S</given-names></string-name>, <string-name><surname>Pieper</surname><given-names>KS</given-names></string-name>, et al. <article-title>Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>124</volume>:<fpage>544</fpage>–<lpage>554</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.047498</pub-id>
<pub-id pub-id-type="pmid">21709065</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0013"><string-name><surname>Watanabe</surname><given-names>H</given-names></string-name>, <string-name><surname>Domei</surname><given-names>T</given-names></string-name>, <string-name><surname>Morimoto</surname><given-names>T</given-names></string-name>, <string-name><surname>Natsuaki</surname><given-names>M</given-names></string-name>, <string-name><surname>Shiomi</surname><given-names>H</given-names></string-name>, <string-name><surname>Toyota</surname><given-names>T</given-names></string-name>, <string-name><surname>Ohya</surname><given-names>M</given-names></string-name>, <string-name><surname>Suwa</surname><given-names>S</given-names></string-name>, <string-name><surname>Takagi</surname><given-names>K</given-names></string-name>, <string-name><surname>Nanasato</surname><given-names>M</given-names></string-name>, et al. <article-title>Effect of 1‐month dual antiplatelet therapy followed by clopidogrel vs 12‐month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT‐2 randomized clinical trial</article-title>. <source>JAMA</source>. <year>2019</year>;<volume>321</volume>:<fpage>2414</fpage>–<lpage>2427</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2019.8145</pub-id>
<pub-id pub-id-type="pmid">31237644</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0014"><string-name><surname>Kim</surname><given-names>BK</given-names></string-name>, <string-name><surname>Hong</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Cho</surname><given-names>YH</given-names></string-name>, <string-name><surname>Yun</surname><given-names>KH</given-names></string-name>, <string-name><surname>Kim</surname><given-names>YH</given-names></string-name>, <string-name><surname>Suh</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cho</surname><given-names>JY</given-names></string-name>, <string-name><surname>Her</surname><given-names>AY</given-names></string-name>, <string-name><surname>Cho</surname><given-names>S</given-names></string-name>, <string-name><surname>Jeon</surname><given-names>DW</given-names></string-name>, et al. <article-title>Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>:<fpage>2407</fpage>–<lpage>2416</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2020.7580</pub-id>
<pub-id pub-id-type="pmid">32543684</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0015"><string-name><surname>Hahn</surname><given-names>JY</given-names></string-name>, <string-name><surname>Song</surname><given-names>YB</given-names></string-name>, <string-name><surname>Oh</surname><given-names>JH</given-names></string-name>, <string-name><surname>Chun</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Park</surname><given-names>YH</given-names></string-name>, <string-name><surname>Jang</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Im</surname><given-names>ES</given-names></string-name>, <string-name><surname>Jeong</surname><given-names>JO</given-names></string-name>, <string-name><surname>Cho</surname><given-names>BR</given-names></string-name>, <string-name><surname>Oh</surname><given-names>SK</given-names></string-name>, et al. <article-title>Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART‐CHOICE randomized clinical trial</article-title>. <source>JAMA</source>. <year>2019</year>;<volume>321</volume>:<fpage>2428</fpage>–<lpage>2437</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2019.8146</pub-id>
<pub-id pub-id-type="pmid">31237645</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38858-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah38858-cit-0016"><string-name><surname>Marquis‐Gravel</surname><given-names>G</given-names></string-name>, <string-name><surname>Hammill</surname><given-names>BG</given-names></string-name>, <string-name><surname>Mulder</surname><given-names>H</given-names></string-name>, <string-name><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>HR</given-names></string-name>, <string-name><surname>Wruck</surname><given-names>LM</given-names></string-name>, <string-name><surname>Sharlow</surname><given-names>A</given-names></string-name>, <string-name><surname>Harris</surname><given-names>DF</given-names></string-name>, <string-name><surname>Pohlman</surname><given-names>FW</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>AF</given-names></string-name>, et al. <article-title>Validation of cardiovascular end points ascertainment leveraging multisource electronic health records harmonized into a common data model in the ADAPTABLE randomized clinical trial</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2021</year>;<volume>14</volume>:<elocation-id>e008190</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.121.008190</pub-id><pub-id pub-id-type="pmid">34886680</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
